HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
cgUyR8WBLqk0nBjn